Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients - PubMed (original) (raw)

Clinical Trial

. 1998 Mar;111(3):248-51.

Affiliations

• PMID: 10374427

Clinical Trial

Effectiveness of the analogue of natural Schisandrin C (HpPro) in treatment of liver diseases: an experience in Indonesian patients

N Akbar et al. Chin Med J (Engl). 1998 Mar.

Abstract

Objective: To determine the effect of dimethyl-4,4'-dimethoxy-5,6, 5',6-dimethylene dioxybiphenyl-2,2'-dicarboxylate (HpPro) on patients with acute and chronic liver diseases.

Methods: An open trial and a prospective randomized and controlled study were performed. The open trial consisted of 56 cases (16 cases of acute hepatitis, 20 cases of chronic hepatitis, 14 cases of liver cirrhosis and 6 cases of fatty liver). Controlled study consisted of 20 cases of Child A chronic hepatitis which were randomly treated with either HpPro or a mixture of known drugs which used as a liver protective agent in Indonesia as control for one week. The patients were then crossed over those two drugs in the next week.

Results: In the open trial, after 4 weeks' treatment with HpPro 7.5 mg orally three times daily, acute hepatitis, chronic hepatitis and fatty liver cases showed rapid decrease of SGOT and SGPT. In the liver cirrhosis cases, SGOT and SGPT were decreased slowly. In the controlled trial, nine patients received HpPro 7.5 mg three times daily orally and eleven were treated with a mixture of known drugs as the controls. After one week treatment, HpPro group clinically showed significant decrease of SGPT and SGOT levels compared to control group (P = 0.035). At the second week, HpPro group showed significant decrease of SGOT compared to control group (P = 0.038) but the decrease of SGPT was not significant (P = 0.096).

Conclusion: Treatment with HpPro is effective to reduce liver impairment in acute and chronic liver diseases on Indonesian patients. No side effect of HpPro was observed.

PubMed Disclaimer

Similar articles

• [The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial].
  Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. Yin SS, et al. Zhonghua Gan Zang Bing Za Zhi. 2004 Aug;12(8):467-70. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15329205 Clinical Trial. Chinese.
• Danshao huaxian capsule in treatment of decompensated cirrhosis resulting from chronic hepatitis B.
  Cheng ML, Lu T, Yao YM, Geng XX. Cheng ML, et al. Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):48-51. Hepatobiliary Pancreat Dis Int. 2006. PMID: 16481282
• [The clinical study on chronic hepatitis B treated by the four-step therapeutics of Traditional Chinese Medicine].
  Yang HZ, Wang FL, Wang YZ, Shen WS, Xu GL, Yang YW, Huang XL. Yang HZ, et al. Zhong Yao Cai. 2006 Jul;29(7):748-52. Zhong Yao Cai. 2006. PMID: 17059015 Clinical Trial. Chinese.
• [Corticosteroids and the liver. Metabolism and indications in liver diseases].
  Uribe M, Ramos MH. Uribe M, et al. Rev Invest Clin. 1983 Jan-Mar;35(1):71-80. Rev Invest Clin. 1983. PMID: 6346450 Review. Spanish. No abstract available.
• [Use of pyrogenal in the overall treatment of infectious diseases (a review of the literature)].
  Zeĭgermakher GA. Zeĭgermakher GA. Vrach Delo. 1980 Feb;(2):105-7. Vrach Delo. 1980. PMID: 6989111 Review. Russian. No abstract available.

Cited by

• Comparative Analysis of the Antioxidative and Hepatoprotective Activities of Dimethyl Diphenyl Bicarboxylate in Four Animal Models of Hepatic Injury.
  Wang JH, Hwang SJ, Son CG. Wang JH, et al. Antioxidants (Basel). 2021 Sep 23;10(10):1508. doi: 10.3390/antiox10101508. Antioxidants (Basel). 2021. PMID: 34679643 Free PMC article.
• Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative?
  Wang C, Xu YQ. Wang C, et al. Gastroenterology Res. 2008 Dec;1(1):2-7. doi: 10.4021/gr2008.10.1231. Epub 2008 Nov 20. Gastroenterology Res. 2008. PMID: 27994699 Free PMC article. Review.
• Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.
  Teschke R, Wolff A, Frenzel C, Eickhoff A, Schulze J. Teschke R, et al. World J Gastroenterol. 2015 Apr 21;21(15):4466-90. doi: 10.3748/wjg.v21.i15.4466. World J Gastroenterol. 2015. PMID: 25914456 Free PMC article. Review.
• New perspectives on chinese herbal medicine (zhong-yao) research and development.
  Pan SY, Chen SB, Dong HG, Yu ZL, Dong JC, Long ZX, Fong WF, Han YF, Ko KM. Pan SY, et al. Evid Based Complement Alternat Med. 2011;2011:403709. doi: 10.1093/ecam/neq056. Epub 2011 Mar 10. Evid Based Complement Alternat Med. 2011. PMID: 21785622 Free PMC article.
• Medicinal herbs for hepatitis C virus infection.
  Liu JP, Manheimer E, Tsutani K, Gluud C. Liu JP, et al. Cochrane Database Syst Rev. 2001;2001(4):CD003183. doi: 10.1002/14651858.CD003183. Cochrane Database Syst Rev. 2001. PMID: 11687177 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information